- Home
- DSAC vs SCTX Comparison
DSAC vs SCTX Comparison
Compare DSAC & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$26.13
Company Overview
Basic Information| Metric | DSAC | SCTX |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.6M | 330.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DSAC | SCTX |
|---|---|---|
| Price | $10.18 | $26.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 86.9K | ★ 251.5K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $17.31 |
| 52 Week High | $10.47 | $26.25 |
Technical Indicators
Market Signals| Indicator | DSAC | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.86 | 64.57 |
| Support Level | $9.90 | N/A |
| Resistance Level | $10.47 | N/A |
| Average True Range (ATR) | 0.01 | 2.76 |
| MACD | -0.00 | 0.49 |
| Stochastic Oscillator | 100.00 | 90.61 |
Price Performance
Historical Comparison DSAC
SCTX
About DSAC Daedalus Special Acquisition Corp. Class A Ordinary Shares
Daedalus Special Acquisition Corp is a blank check company.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.